Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Kiran Mazumdar-Shaw Stories

2014-01-21 16:21:23

She will accept CHF's top award at a dinner ceremony, the premier event of Heritage Day 2014 in Philadelphia. PHILADELPHIA, Jan. 21, 2014 /PRNewswire-USNewswire/ -- Kiran Mazumdar-Shaw, chairman and managing director, Biocon Limited, will receive the 2014 Othmer Gold Medal at the Chemical Heritage Foundation on Thursday, May 15. The Othmer Gold Medal presentation will be the premier event of CHF's 13th annual Heritage Day. (Photo:...

2013-02-13 16:26:51

PITTSBURGH, Feb. 13, 2013 /PRNewswire/ -- Mylan (Nasdaq: MYL) today announced that it has entered into a definitive agreement with Biocon Limited for an exclusive strategic collaboration on the development and commercialization of generic versions of three insulin analog products. Mylan CEO Heather Bresch commented, "This collaboration builds off of our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products....

2012-05-02 18:21:41

MUMBAI and BANGALORE, India, May 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT), one of India's largest health care companies, today announced plans to establish its first nutrition research and development center in the country in collaboration with Syngene, India's leading contract research organization. The Abbott Nutrition R&D Center in India will focus on the development of science-based, affordable nutrition products for the country and enable the expansion of Abbott's nutrition product...

2010-10-18 06:00:00

BANGALORE, India and NEW YORK, Oct. 18 /PRNewswire/ -- Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Pfizer will have exclusive rights to commercialize these products globally,...

2010-05-24 07:00:00

SAN DIEGO and BANGALORE, India, May 24 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) a biopharmaceutical company focused on the treatment of serious infections such as Clostridium difficile infection (CDI), and Biocon Limited (NSE: BIOCON), one of India's premier biotechnology companies and a global provider of manufacturing services, announced today that they have entered into a long-term supply agreement for the commercial manufacturing of the active...

2009-09-10 15:15:00

SAN DIEGO and BANGALORE, India, Sept. 10 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid"...

2009-06-29 05:30:00

PITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has executed a definitive agreement with Biocon Limited, a publicly traded company on the Indian stock exchanges, for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace. Through this partnership, Mylan and Biocon bring together highly complementary capabilities that will...

2008-07-18 09:01:12

Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Abraxane is now available in India as a single-use 100mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). In October 2007, Abraxane was approved by the Drug Controller General of India. The approval was based on the clinical trial data that was...